Synergy CHC Corp. 10-Q

10-Q 1 form10-q.htm U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Synergy CHC Corp. Nevada 000-55098 99-0379440 (State or other jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification Number) 865 Spring Street Westbrook, Maine 04092 (Address of principal executive offices) (615) 939-9004 (Issuer’s Telephone Number) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every, Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Sec.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ] Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule12b-2 of the Exchange Act. Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [X] (Do not check if smaller reporting company) Emerging Growth Company [ ] If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ] Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X] APPLICABLE ONLY TO CORPORATE ISSUERS Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of August 13, 2018, 89,862,683 shares of our common stock were issued and outstanding. SYNERGY CHC CORP. INDEX Table of Contents PART I FINANCIAL INFORMATION Item 1. Condensed consolidated financial statements 3 Condensed consolidated balance sheets as of June 30, 2018 (unaudited) and December 31, 2017 3 Condensed consolidated statements of operations and comprehensive (loss) income for the three and six months ended June 30, 2018 and 2017 (unaudited) 4 Condensed consolidated statements of cash flows for the six months ended June 30, 2018 and 2017 (unaudited) 5 Notes to unaudited condensed consolidated financial statements 6 Item 2. Management’s discussion and analysis of financial condition and results of operations 22 Item 3. Quantitative and qualitative disclosures about market risk 27 Item 4. Controls and procedures 27 PART II OTHER INFORMATION Item 1. Legal proceedings 28 Item 1A. Risk factors 28 Item 2. Unregistered sales of equity securities and use of proceeds 28 Item 3. Defaults upon senior securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other information 28 Item 6. Exhibits 28 Signatures 29 2 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS Synergy CHC Corp. Condensed Consolidated Balance Sheets June 30, 2018 December 31, 2017 (Unaudited) Assets Current Assets: Cash and cash equivalents $ 865,812 $ 1,955,614 Restricted cash 138,023 139,071 Accounts receivable, net 4,089,042 4,333,608 Prepaid expenses 925,472 1,143,251 Inventory, net 3,156,214 2,842,376 Total Current Assets 9,174,563 10,413,920 Fixes assets, net 346,131 293,205 Goodwill 7,793,240 7,793,240 Intangible assets, net 4,766,148 5,532,210 Total Assets $ 22,080,082 $ 24,032,575 Liabilities and Stockholders’ Equity Current Liabilities: Accounts payable and accrued liabilities $ 4,144,478 $ 4,328,548 Deferred revenue 40,901 3,058 Provision for income taxes payable 376,018 94,956 Current portion of long-term debt, net of debt discount and debt issuance cost, related party 1,936,862 2,487,233 Current portion of royalty payable 118,617 221,222 Total Current Liabilities 6,616,876 7,135,017 Long-term Liabilities: Note payable, net of debt discount and debt issuance cost, related party 6,526,027 7,464,279 Total Long-term Liabilities 6,526,027 7,464,279 Total Liabilities 13,142,903 14,599,296 Commitments and contingencies Stockholders’ Equity: Common stock, $0.00001 par value; 300,000,000 shares authorized; 89,862,683 and 89,862,683 shares issued and outstanding, respectively 899 899 Additional paid in capital 18,616,187 18,376,801 Accumulated other comprehensive income (loss) 25,415 (77,988 ) Accumulated deficit (9,705,322 ) (8,866,432 ) Total stockholders ’ equity 8,937,179 9,433,279 Total Liabilities and Stockholders’ Equity $ 22,080,082 $ 24,032,575 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements 3 Synergy CHC Corp. Unaudited Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income For the three months ended For the six months ended June 30, 2018 June 30, 2017 June 30, 2018 June 30, 2017 Revenue $ 9,728,712 $ 9,318,918 $ 19,429,573 $ 20,107,237 Cost of sales 2,744,760 2,462,424 5,554,668 4,964,954 Gross profit 6,983,952 6,856,494 13,874,905 15,142,283 Operating expenses Selling and marketing 5,148,656 4,223,712 9,401,359 7,120,909 General and administrative 1,475,289 2,367,969 3,236,145 4,305,612 Depreciation and amortization 455,951 357,111 907,437 649,429 Total operating expenses 7,079,896 6,948,792 13,544,941 12,075,950 (Loss) income from operations (95,944 ) (92,298 ) 329,964 3,066,333 Other (income) expenses Interest income 1,011 5 (71 ) (10 ) Interest expense 305,687 187,077 575,863 434,441 Remeasurement loss (gain) on translation of foreign subsidiary 120,623 (105,974 ) 131,321 (91,731 ) Loss on sale of assets - - - 2,877 Amortization of debt issuance cost 37,739 44,531 78,735 88,572 Total other expenses 465,060 125,639 785,848 434,149 Net (loss) income before income taxes (561,004 ) (217,937 ) (455,884 ) 2,632,184 Income tax (benefit) expense 222,389 (167,756 ) 383,002 123,711 Net (loss) income after tax $ (783,393 ) $ (50,181 ) $ (838,886 ) $ 2,508,473 Net (loss) income per share – basic $ (0.01 ) $ (0.00 ) $ (0.01 ) $ 0.03 Net (loss) income per share – diluted $ (0.01 ) $ (0.00 ) $ (0.01 ) $ 0.03 Weighted average common shares outstanding Basic 89,862,683 88,811,169 89,862,683 88,787,893 Diluted 89,862,683 88,811,169 89,862,683 88,912,893 Comprehensive (loss) income: Net (loss) income (783,393 ) (50,181 ) (838,886 ) 2,508,473 Foreign currency translation adjustment 42,891 (23,231 ) 103,404 (29,132 ) Comprehensive (loss) income $ (740,502 ) $ (73,412 ) $ (735,482 ) $ 2,479,341 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements 4 Synergy CHC Corp. Unaudited Condensed Consolidated Statements of Cash Flows For the six months ended June 30, 2018 June 30, 2017 Cash Flows from Operating Activities Net (loss) income $ (838,886 ) $ 2,508,473 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Depreciation and amortization 907,437 649,429 Amortization of debt issuance cost 78,735 88,572 Stock based compensation expense 239,386 680,679 Remeasurement loss (gain) on translation of foreign subsidiary 131,321 (91,731 ) Foreign currency transaction loss 30,931 127,893 Non cash implied interest 42,535 44,598 Loss on sale of fixed assets - 2,877 Changes in operating assets and liabilities: Accounts receivable 244,566 802,827 Inventory (313,838 ) 379,062 Prepaid expense 217,779 (45,201 ) Accounts payable and accrued liabilities (65,263 ) (1,820,920 ) Deferred revenue 37,843 (25,187 ) Net cash provided by operating activities 712,546 3,301,371 Cash Flows from Investing Activities Payments for acquisition of fixed assets (129,087 ) (76,534 ) Payment for acquisition of domain name (15,213 ) - Proceeds from sale of assets - 6,199 Payment of development fee - (761,935 ) Purchase of intangible assets (50,000 ) - Net cash used in investing activities (194,300 ) (832,270 ) Cash Flows from Financing Activities Repayment of notes payable (1,712,500 ) (4,025,000 ) Net cash used in financing activities (1,712,500 ) (4,025,000 ) Effect of exchange rate on cash, cash equivalents and restricted cash 103,404 (29,134 ) Net decrease in cash, cash equivalents and restricted cash (1,090,850 ) (1,585,033 ) Cash, Cash Equivalents and restricted cash, beginning of period 2,094,685 2,617,642 Cash, Cash Equivalents and restricted cash, end of period $ 1,003,835 $ 1,032,609 Supplemental Disclosure of Cash Flow Information: Cash paid during the period for: Interest $ 700,197 $ 427,601 Income taxes $ 85,639 $ 1,048,120 Supplemental Disclosure of Non-cash Investing and Financing Activities: Common stock issued for the acquisition of assets of Per-fekt $ - $ 241,396 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements 5 Synergy CHC Corp. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1 – Nature of the Business Synergy CHC Corp. (“Synergy”, “we”, “us”, “our” or the “Company”) (formerly Synergy Strips Corp.) was incorporated on December 29, 2010 in Nevada under the name “Oro Capital Corporation.” On April 21, 2014, the Company changed its fiscal year end from July 31 to December 31. On April 28, 2014, the Company changed its name to “Synergy Strips Corp.”. On August 5, 2015, the Company changed its name to “Synergy CHC Corp.” The Company is a consumer health care company that is in the process of building a portfolio of best-in-class consumer product brands. Synergy’s strategy is to grow its portfolio both organically and by further acquisition. Synergy is the sole owner of six subsidiaries: Neuragen Corp., Breakthrough Products, Inc., NomadChoice Pty Ltd., Synergy CHC Inc., Sneaky Vaunt Corp. and The Queen Pegasus Corp. and the results have been consolidated in these statements. Note 2 – Summary of Significant Accounting Policies General The accompanying condensed consolidated financial statements as of June 30, 2018 and December 31, 2017 and for the three and six months ended June 30, 2018 and 2017 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Rule S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2018. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2017 and footnotes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on April 2, 2018. Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates are assumptions about collection of accounts receivable, useful life of fixed and intangible assets, goodwill and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate, and expected dividend rate. Cash and Cash Equivalents The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of June 30, 2018, the Company had no cash equivalents. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At June 30, 2018, the uninsured balance amounted to $369,095. Capitalization of Fixed Assets The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred. 6 Intangible Assets We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization except intellectual property of $1,450,000 acquired as part of an Asset Purchase Agreement entered into with Factor Nutrition Labs LLC on January 22, 2015, $10,000 acquired as part of an Asset Purchase Agreement entered into with Perfekt Beauty Holdings LLC and CDG Holdings, LLC on June 21, 2017 and $50,000 acquired as an Asset Purchase entered into with Cocowhite on May 22, 2018. Intangible assets are amortized on a straight line basis over the useful lives. As of June 30, 2018, our qualitative analysis of intangible assets with indefinite lives did not indicate any impairment. Long-lived Assets Long-lived assets include equipment and intangible assets other than those with indefinite lives. We assess the carrying value of our long-lived asset groups when indicators of impairment exist and recognize an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset. Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value. As of June 30, 2018, our qualitative analysis of long-lived assets did not indicate any impairment. Goodwill An asset purchase is accounted for under the purchase method of accounting. Under that method, assets and liabilities of the business acquired are recorded at their estimated fair values as of the date of the acquisition, with any excess of the cost of the acquisition over the estimated fair value of the net tangible and intangible assets acquired recorded as goodwill. As of June 30, 2018, our qualitative analysis of goodwill did not indicate any impairment. Revenue Recognition Adoption of ASU 2014-09, Revenue from Contracts with Customers On January 1, 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606) using the modified retrospective (cumulative effect) transition method. Under this transition method, results for reporting periods beginning January 1, 2018 or later are presented under ASC 606, while prior period results continue to be reported in accordance with previous guidance. The cumulative effect of the initial application of ASC 606 was immaterial, no adjustment was recorded to the opening balance of retained earnings. The timing of revenue recognition for our various revenue streams was not materially impacted by the adoption of this standard. The Company believes its business processes, systems, and controls are appropriate to support recognition and disclosure under ASC 606. In addition, the adoption has led to increased footnote disclosures. Overall, the adoption of ASC 606 did not have a material impact on the Company’s condensed consolidated balance sheet, statement of operations and comprehensive income and statement of cash flows for the six months ended June 30, 2018. ASC 606 also requires additional disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. As described below, the analysis of contracts under ASC 606 supports the recognition of revenue at a point in time, resulting in revenue recognition timing that is materially consistent with the Company’s historical practice of recognizing product revenue when title and risk of loss pass to the customer. Policy The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification (“ASC”) ASC 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. The Company recognizes revenue upon shipment from its fulfillment centers. Certain of our distributors may also perform a separate function as a co-packer on our behalf. In such cases, ownership of and title to our products that are co-packed on our behalf by those co-packers who are also distributors, passes to such distributors when we are notified by them that they have taken transfer or possession of the relevant portion of our finished goods. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Cancelled orders are refunded if not already dispatched, refunds are only paid if stock is damaged in transit, discounts are only offered with specific promotions and orders will be refilled if lost in transit. Contract Assets The Company does not have any contract assets such as work-in-process. All trade receivables on the Company’s condensed consolidated balance sheet are from contracts with customers. Contract Costs Costs incurred to obtain a contract are capitalized unless short term in nature. As a practical expedient, costs to obtain a contract that are short term in nature are expensed as incurred. The Company does not have any contract costs capitalized as of June 30, 2018. Contract Liabilities - Deferred Revenue The Company’s contract liabilities consist of advance customer payments and deferred revenue. Deferred revenue results from transactions in which the Company has been paid for products by customers, but for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, the deferred revenues are recognized. Accounts receivable Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts. Advertising Expense The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in selling expense in the accompanying unaudited condensed consolidated statements of income. Research and Development Costs incurred in connection with the development of new products and processing methods are charged to general and administrative expenses as incurred. Income Taxes The Company utilizes FASB ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. 7 The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration. NomadChoice Pty Ltd, the Company’s wholly-owned foreign subsidiary, is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made. Synergy CHC Inc. is a wholly-owned foreign subsidiary, is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made. Net Earnings (Loss) Per Common Share The Company computes earnings per share under ASC subtopic 260-10, Earnings Per Share. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted earnings per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the “treasury stock” method), unless their effect on net loss per share is anti-dilutive. As of June 30, 2018 and 2017, options to purchase 8,666,667 and 6,300,000 shares of common stock, respectively, were outstanding. As of both June 30, 2018 and 2017, warrants to purchase 1,000,000 shares of common stock were outstanding. The following is a reconciliation of the number of shares used in the calculation of basic earnings per share and diluted earnings per share for the three and six months ended June 30, 2018, and 2017: For the three months ended For the six months ended June 30, 2018 June 30, 2017 June 30, 2018 June 30, 2017 Net income after tax $ (783,393 ) $ (50,181 ) $ (838,886 ) 2,508,473 Weighted average common shares outstanding 89,862,683 88,811,169 89,862,683 88,787,893 Common stock to be issued - - - 125,000 Incremental shares from the assumed exercise of dilutive stock options - - - - Incremental shares from the assumed exercise of dilutive stock warrants - - - - Dilutive potential common shares 89,862,683 88,811,169 89,862,683 88,912,893 Net earnings per share: Basic $ (0.01 ) $ (0.00 ) $ (0.01 ) $ 0.03 Diluted $ (0.01 ) $ (0.00 ) $ (0.01 ) $ 0.03 The following securities were not included in the computation of diluted net earnings per share as their effect would have been antidilutive: 2018 2017 Options to purchase common stock 8,666,667 6,300,000 Warrants to purchase common stock 1,000,000 1,000,000 9,666,667 7,300,000 Fair Value Measurements The Company measures and discloses the fair value of assets and liabilities required to be carried at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value, and enhances fair value measurement disclosure. 8 ASC 825 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date. Level 2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 - Unobservable inputs for the asset or liability. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. As of June 30, 2018, the Company has determined that there were no assets or liabilities measured at fair value. Inventory Inventory consists of raw materials, components and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or net realizable value. Finished goods include the cost of labor to assemble the items. Stock-Based Compensation ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. Foreign Currency Translation The functional currency of one of the Company’s foreign subsidiaries (Nomadchoice Pty Ltd.) is the U.S. Dollar. The Company’s foreign subsidiary maintains its records using local currency (Australian Dollar). All monetary assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at quarter end exchange rates, non-monetary assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at transaction day exchange rates. Income and expense items related to non-monetary items were translated at exchange rates prevailing during the transaction date and other incomes and expenses were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, were recorded in statements of operations as Remeasurement gain or loss on translation of foreign subsidiary. The functional currency of the Company’s other foreign subsidiary (Synergy CHC Inc.) is the Canadian Dollar (CAD). The Company’s foreign subsidiary maintains its records using local currency (CAD). All assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at period end exchange rates and stockholders’ equity is translated at the historical rates. Income and expense items were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, are reported as other comprehensive income and accumulated other comprehensive income in the stockholder’s equity in accordance with ASC 220 – Comprehensive Income. Translation gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are translated into either Australian Dollars or Canadian Dollars, as the case may be, at the rate on the date of the transaction and included in the results of operations as incurred. 9 Concentrations of Credit Risk In the normal course of business, the Company provides credit terms to its customers; however, collateral is not required. Accordingly, the Company performs credit evaluations of its customers and maintains allowances for possible losses which, when realized, were within the range of management’s expectations. From time to time, a higher concentration of credit risk exists on outstanding accounts receivable for a select number of customers due to individual buying patterns. Warehousing costs Warehouse costs include all third party warehouse rent fees and are charged to selling and marketing expenses as incurred. Any additional costs relating to assembly or special pack-outs of the Company’s products are charged to cost of sales. Product display costs All displays manufactured and purchased by the Company are for placement of product in retail stores. This also includes all costs for display execution and setup and retail services are charged to cost of sales and expensed as incurred. Cost of Sales Cost of sales includes the purchase cost of products sold and all costs associated with getting the products into the retail stores including buying and transportation costs. Debt Issuance Costs Debt issuance costs consist primarily of arrangement fees, professional fees and legal fees. These costs are netted off with the related loan and are being amortized to interest expense over the term of the related debt facilities. Shipping Costs Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in selling and marketing expenses. Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged. Segment Reporting Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis. 10 Recent Accounting Pronouncements ASU 2018-05 This Accounting Standards Update adds SEC paragraphs pursuant to the SEC Staff Accounting Bulletin No. 118, which expresses the view of the staff regarding application of Topic 740, Income Taxes, in the reporting period that includes December 22, 2017 - the date on which the Tax Cuts and Jobs Act (H.R.1, An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018) was signed into law. We are currently evaluating the impact of adopting ASU 2017-13 on our consolidated financial statements. ASU 2018-02 On December 22, 2017, the U.S. federal government enacted a tax bill, H.R.1, An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018 (Tax Cuts and Jobs Act of 2017). Stakeholders raised a narrow-scope financial reporting issue that arose as a consequence of the Tax Cuts and Jobs Act of 2017. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017. The amendments in this Update affect any entity that is required to apply the provisions of Topic 220, Income Statement-Reporting Comprehensive Income, and has items of other comprehensive income for which the related tax effects are presented in other comprehensive income as required by GAAP. The amendments in this update is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this Update should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2018-210—Income Statement—Reporting Comprehensive Income (Topic 220), which has been deleted. We are currently evaluating the impact of adopting ASU 2017-13 on our consolidated financial statements. ASU 2018-01 The amendments in this Update provide an optional transition practical expedient to not evaluate under Topic 842 existing or expired land easements that were not previously accounted for as leases under Topic 840, Leases. An entity that elects this practical expedient should evaluate new or modified land easements under Topic 842 beginning at the date that the entity adopts Topic 842. An entity that does not elect this practical expedient should evaluate all existing or expired land easements in connection with the adoption of the new lease requirements in Topic 842 to assess whether they meet the definition of a lease. We are currently evaluating the impact of adopting ASU 2017-13 on our consolidated financial statements. ASU 2017-13 In September 2017, the FASB issued Accounting Standard Update (ASU) 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842). The effective date for ASU 2017-13 is for fiscal years beginning after December 15, 2018. We have adopted ASC 606 as disclosed above. We are currently evaluating the impact of adopting Leases Topic 840 ASU 2017-13 on our consolidated financial statements. ASU 2017-09 The Board is issuing this Update to provide clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendment is Effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. This Update is the final version of Proposed Accounting Standards Update 2016-360—Compensation—Stock Compensation (Topic 718)—Scope of Modification Accounting, which has been deleted. Adoption of this new standard did not have any impact on the Company’s consolidated financial statements. ASU 2017-04 In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350), which simplifies the goodwill impairment test. The effective date for ASU 2017-04 is for fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact of adopting ASU 2017-04 on our consolidated financial statements. ASU No. 2017-01 In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for the Company on January 1, 2018; however, early adoption is permitted with prospective application to any business development transaction. We are currently evaluating the impact of adopting ASU 2017-04 on our consolidated financial statements. 11 ASU 2016-18 In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230), which requires that restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total cash amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. We adopted ASU 2016-18 effective January 1, 2018. The adoption of ASU 2016-18 had no impact on our retained earnings, and no impact to our net income on an ongoing basis. Adoption of the new standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash, or restricted cash equivalents. The amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statements of cash flows. The amendments have been applied using a retrospective transition method to each period presented, as required. The period ended June 30, 2017 has been reclassified to reflect this change. ASU 2016-15 In August 2016, the FASB issued AS 2016-15, Classification of Certain Cash Receipts and Cash Payments, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The effective date for ASU 2016-15 is for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. We are currently evaluating the impact of adopting ASU 2016-18 on our consolidated financial statements. ASU 2016-09 In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation, or ASU No. 2016-09. The areas for simplification in this Update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in this Update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term should be applied prospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. We are currently evaluating the impact of adopting ASU No. 2016-09 on our consolidated financial statements. ASU 2016-01 In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements. 12 Note 3 – Inventory Inventory consists of finished goods, components and raw materials. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or net realizable value. The carrying value of inventory consisted of the following: June 30, 2018 December 31, 2017 Finished goods $ 2,101,306 $ 1,507,344 Components 767,021 1,197,228 Inventory in transit 168,948 45,188 Raw materials 118,939 92,616 Total inventory $ 3,156,214 $ 2,842,376 On January 22, 2015, inventory was pledged to Knight Therapeutics under the Loan Agreement (see note 10). 13 Note 4 – Accounts Receivable Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following: June 30, 2018 December 31, 2017 Trade accounts receivable $ 4,089,042 $ 4,333,608 Less allowances - - Total accounts receivable, net $ 4,089,042 $ 4,333,608 Note 5 – Prepaid Expenses Prepaid expenses consisted of the following: June 30, 2018 December 31, 2017 Advances for inventory $ 87,687 $ 206,973 Components - 104,668 Media production 62,375 109,388 Insurance 45,243 41,548 Trade shows 8,600 17,150 Deposits 47,375 44,841 Rent - 19,500 Promotion - Bloggers 139,790 246,592 License agreement 108,334 158,333 Software subscriptions 83,302 20,513 Rebranding 110,961 32,841 Clinical Research 43,532 47,490 Advertising 49,611 2,500 Promotions - 37,500 Miscellaneous 138,662 53,414 Total $ 925,472 $ 1,143,251 Note 6 – Concentration of Credit Risk Cash and cash equivalents The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At June 30, 2018 and December 31, 2017, the uninsured balances amounted to $369,095 and $1,557,373, respectively. Accounts receivable As of June 30, 2018, four customers accounted for 89% of the Company’s accounts receivable. As of December 31, 2017, three customers accounted for 88% of the Company’s accounts receivable. Major customers For the six months ended June 30, 2018, three customers accounted for approximately 44% of the Company’s net revenue. For the three months ended June 30, 2018, three customers accounted for approximately 47% of the Company’s net revenue. For the six months ended June 30, 2017, three customers accounted for approximately 35% of the Company’s net revenue. For the three months ended June 30, 2017, three customers accounted for approximately 32% of the Company’s net revenue. For the year ended December 31, 2017, two customers accounted for approximately 42% of the Company’s net revenues. Substantially all of the Company’s business is with companies in the United States. Major suppliers For the three and six months ended June 30, 2018 and the year ended December 31, 2017, our products were made by the following suppliers: FOCUSfactor Atrium Innovations - Pittsburgh, PA Vit-Best Nutrition, Inc. - Tustin, CA Flat Tummy Tea Caraway Tea Company, LLC - Highland, NY - Neuragen C-Care, LLC - Linthicum Heights, MD - UrgentRx Capstone Nutrition - Ogden, UT - Hand MD HealthSpecialty - Santa Fe Springs, CA - Sneaky Vaunt Dongguan Jingrui – China - The Queen Pegasus Skin Actives – Gilbert, AZ Ningbo Beautiful Daily Cosmetics – Zhejiang, China It is the opinion of management that the products can be produced by other manufacturers and the choice to utilize these suppliers is not a significant concentration. 14 Note 7 – Fixed Assets and Intangible Assets As of June 30, 2018, and December 31, 2017, fixed assets and intangible assets consisted of the following: June 30, 2018 December 31, 2017 Property and equipment $ 566,445 $ 437,358 Less accumulated depreciation (220,314 ) (144,153 ) Fixed assets, net $ 346,131 $ 293,205 Depreciation expense for the three months ended June 30, 2018 and 2017 was $39,754 and $25,246, respectively. Depreciation expense for the six months ended June 30, 2018 and 2017 was $76,162 and $50,311, respectively. June 30, 2018 December 31, 2017 FOCUSfactor intellectual property $ 1,450,000 $ 1,450,000 Perfekt intellectual property 10,000 10,000 Cocowhite intellectual property 50,000 - Intangible assets subject to amortization 7,150,165 7,134,952 Less accumulated amortization (3,894,017 ) (3,062,742 ) Intangible assets, net $ 4,766,148 $ 5,532,210 Amortization expense for the three months ended June 30, 2018 and 2017 was $416,197 and $331,866, respectively. Amortization expense for the six months ended June 30, 2018 and 2017 was $831,275 and $599,119, respectively. These intangible assets were acquired through an Asset Purchase Agreement and Stock Purchase Agreements. During the current period we purchased intangible assets related to Cocowhite for $50,000. Note 8 – Related Party Transactions The Company accrued and paid consulting fees of $57,917 for four months to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company. The Company expensed $171,917 during the three months ended June 30, 2018 and $229,833 during the six months ended June 30, 2018. As of June 30, 2018, the total outstanding balance was $0 for consulting fees and reimbursements. On January 22, 2015, the Company entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc. (“Knight”), a related party, for the purchase of the Focus Factor assets. At June 30, 2018, the Company owed Knight $0 on this loan, net of debt issuance cost (see Note 10). On June 26, 2015, the Company entered into a Security Agreement with Knight Therapeutics, Inc., through its wholly owned subsidiary Neuragen Corp., for the purchase of Knight Therapeutics, Inc.’s assets. At June 30, 2018, the Company owed Knight $277,381 in relation to this agreement (see Note 10). On August 18, 2015, the Company entered into a Consulting Agreement with Kara Harshbarger, the co-founder of Hand MD, LLC, pursuant to which she will provide marketing and sales related service. The Company pays Ms. Harshbarger $10,000 a month for one year unless the Consulting Agreement is terminated earlier by either party. The Company has extended this agreement on a month to month basis. Hand MD, LLC is a 50% owner in Hand MD Corp. The Company expensed $30,000 through payroll for the three months ended June 30, 2018 and $60,000 for the six months ended June 30, 2018. As of June 30, 2018, the total outstanding balance was $0. On November 12, 2015, the Company entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc., a related party, for the purchase of NomadChoice Pty Limited and Breakthrough Products, Inc. At June 30, 2018, the Company owed Knight $0 on this loan, net of debt issuance cost (see Note 10). The Company expensed royalty of $132,987 during the three months ended June 30, 2018 and $280,009 during the six months ended June 30, 2018. At June 30, 2018 NomadChoice Pty Ltd., a subsidiary of the Company, owed Knight Therapeutics $268,986 in connection with a royalty distribution agreement. The Company expensed royalty of $3,954 during the three months ended June 30, 2018 and $9,616 during the six months ended June 30, 2018. At June 30, 2018 Sneaky Vaunt Corp., a subsidiary of the Company, owed Knight Therapeutics $8,954 in connection with a royalty distribution agreement. The Company expensed commissions of $14,078 during the three months ended June 30, 2018 and $27,631 during the six months ended June 30, 2018. At June 30, 2018, Sneaky Vaunt Corp., a subsidiary of the Company, owed Founded Ventures, owned by a shareholder in the Company, $9,059 in connection with a commission agreement. The Company expensed royalty of $347 during the three months ended June 30, 2018 and $1,911 during the six months ended June 30, 2018. At June 30, 2018 The Queen Pegasus, a subsidiary of the Company, owed Knight Therapeutics $678 in connection with a royalty distribution agreement. The Company expensed commissions of $2,905 during the three months ended June 30, 2018 and $5,890 during the six months ended June 30, 2018. At June 30, 2018, The Queen Pegasus, a subsidiary of the Company, owed Founded Ventures $1,439 in connection with a commission agreement. The Company paid $62,500 and $125,000 during the three and six months ended June 30, 2018 to Hand MD, Corp, related to a royalty agreement. At June 30, 2018, the Company owed Hand MD Corp. $118,617 in minimum future royalties. 15 Note 9 – Accounts Payable and Accrued Liabilities As of June 30, 2018 and December 31, 2017, accounts payable and accrued liabilities consisted of the following: June 30, 2018 December 31, 2017 Accrued payroll $ 241,819 $ 296,491 Accrued legal fees 71,502 96,017 Accounting fees 61,961 19,681 Commissions 131,860 178,286 Manufacturers 2,774,318 2,147,751 Promotions 206,465 897,925 Professional Fees 88,533 45,921 Rent - 19,500 Customers 17,278 106,395 Interest - 147,000 Royalties, related party 358,151 138,143 Warehousing 23,534 10,388 Others 169,057 225,050 Total $ 4,144,478 $ 4,328,548 Note 10 – Notes Payable The Company’s loans payable at June 30, 2018 and December 31, 2017 are as follows: June 30, 2018 December 31, 2017 Loans payable $ 8,777,381 $ 10,344,739 Unamortized debt issuance cost (314,492 ) (393,227 ) Total 8,462,889 9,951,512 Less: Current portion (1,936,862 ) (2,487,233 ) Long-term portion $ 6,526,027 $ 7,464,279 $6,000,000 January 22, 2015 Loan: On January 22, 2015, the Company entered into a Loan and Security Agreement (“Loan Agreement”) with Knight Therapeutics (Barbados) Inc. (“Knight”), pursuant to which Knight agreed to loan the Company $6.0 million (the “Loan”), and which amount was borrowed at closing (the “Financing”) for the purpose of acquiring the Focus Factor Business (defined below). At closing, the Company paid Knight an origination fee of $120,000 and a work fee of $60,000 and also paid $40,000 of Knight’s expenses associated with the Loan. The Loan bears interest at a rate of 15% per year; provided, however, that upon the occurrence of an equity or convertible equity offering by the Company of at least $1.0 million, the interest rate will drop to 13% per year. Interest accrues quarterly and is payable in arrears on March 31, June 30, September 30 and December 31 in each year, beginning on March 31, 2015. All outstanding principal and accrued and unpaid interest is due on the earliest to occur of either January 20, 2017 (the “Maturity Date”), or the date that Knight, in its discretion, accelerates the Company’s obligations due to an event of default. The Company may extend the Maturity Date for two successive additional 12-month periods if at March 31, 2016 and March 31, 2017, respectively, the Company’s revenues exceed $13.0 million and its EBITDA exceeds $2.0 million for the respective 12-month period then ending. These covenants were achieved, therefore the Company chose to extend the loan for the first 12-month period to January 20, 2018. Principal payments under the Loan Agreement commenced on June 30, 2015 and continue quarterly as set forth on the Repayment Schedule to the Loan Agreement. This Loan was repaid in full on January 20, 2018. The Company recognized and paid interest expense of $0 and $4,611, respectively during the three and six months ended June 30, 2018. Accrued interest expense was $0 as of June 30, 2018. Subject to certain restrictions, the Company may prepay the outstanding principal of the Loan (in whole but not in part) at any time if the Company pays a concurrent prepayment fee equal to the greater of (i) the total unpaid annual interest that would have been payable during the year in which the prepayment is made if the prepayment is made prior to the first anniversary of the closing, and (ii) $300,000. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in all present and future assets of the Company. The Company also agreed to not pledge or otherwise encumber its intellectual property assets, subject to certain customary exceptions. The Loan Agreement includes customary representations, warranties, and affirmative and restrictive covenants, including covenants to attain and maintain certain financial metrics, and to not merge or dispose of assets, acquire other businesses (except for businesses substantially similar or complementary to the Company’s business and the aggregate consideration to be paid does not exceed $100,000) or make capital expenditures in excess of $100,000 over the Company’s annual business plan in any year. The Loan Agreement also includes customary events of default, including payment defaults, breaches of covenants, change of control and material adverse effect default. Upon the occurrence of an event of default and during the continuation thereof, the principal amount of the Loan will bear a default interest rate of an additional 5%. 16 In connection with the Loan Agreement, the Company issued to Knight a warrant that entitled Knight to purchase 4,595,187 shares of common stock of the Company (“Common Stock”) on or prior to close of business on January 30, 2015 (the “ST Warrant”). The aggregate exercise price of the Common Stock under the ST Warrant is $1.00. Knight exercised the ST Warrant on January 22, 2015. Also in connection with the Loan Agreement, the Company issued to Knight a warrant to purchase 3,584,759 shares of Common Stock on or prior to the close of business of January 22, 2025 (the “LT Warrant”). The exercise price per share of the Common Stock under the LT Warrant is $0.34. The LT Warrant provides for cashless exercise. The LT Warrant also provides that in the event the closing price of the Common Stock remains above $1.00 for six consecutive months, Knight will forfeit the difference between the number of shares acquired under the LT Warrant prior to 90 days after such six-month period, and 25% of the shares purchasable under the LT Warrant. The beneficial conversion feature of the warrants issued to Knight amounted to $1,952,953 (ST warrants) and $1,462,560 (LT warrants), respectively, and was recorded as debt discount of the corresponding debt. During 2016, this debt discount was fully expensed in conjunction with the cancellation of all warrants and options held by Knight. The Company also recorded deferred financing costs of $289,045 with respect to the above loan. The Company recognized amortization of deferred financing costs of $0 and $3,257 during the three and six months ended June 30, 2018, respectively. Unamortized debt issuance cost as of June 30, 2018 amounted to $0. $950,000 June 26, 2015 Security Agreement: On June 26, 2015, the Company, through its wholly owned subsidiary, Neuragen Corp. (“Neuragen”), issued a 0% promissory note in a principal amount of $950,000 in connection with an Asset Purchase Agreement. The note requires $250,000 to be paid on or before June 30, 2016, and $700,000 to be paid in quarterly installments (beginning with the quarter ended September 30, 2015) equal to the greater of $12,500 or 5% of U.S. net sales, and 2% of U.S. net sales of Neuragen for 60 months thereafter. The payment of such amounts is secured by a security interest in certain assets, undertakings and property (“Collateral”) pursuant to the Security Agreement, which will be released upon receipt of total payments of $1.2 million. The Company also recorded deferred financing costs of $10,486 with respect to the above agreement. The Company recognized amortization of deferred financing costs of $0 during the three and six months ended June 30, 2018. Unamortized debt issuance cost as of June 30, 2018 amounted to $0. The Company recorded present value of future payments of $277,381 and $282,240 as of June 30, 2018 and December 31, 2017, respectively. The Company recorded imputed interest expense of $10,026 and $20,141 for the three and six months ended June 30, 2018, respectively. During the three and six months ended June 30, 2018, the Company made payments of $12,500 and $25,000, respectively, in connection with this Security Agreement. $5,500,000 November 12, 2015 Loan: On November 12, 2015, we entered into a First Amendment to Loan Agreement (“First Amendment”) with Knight, pursuant to which Knight agreed to loan us an additional $5.5 million, and which amount was borrowed at closing (the “Financing”) for the purpose of acquiring Breakthrough Products, Inc. and NomadChoice Pty Limited through Stock Purchase Agreements. At closing, we paid Knight an origination fee of $110,000 and a work fee of $55,000 and also paid $24,000 of Knight’s expenses associated with the Loan. The Loan bears interest at a rate of 15% per year. The interest rate will decrease to 13% if we meet certain equity-fundraising targets. The amended Loan Agreement matured on November 11, 2017 and was fully paid. In connection with the First Amendment, we issued Knight a warrant that entitles Knight to purchase 5,550,625 shares of our common stock (“Knight Warrant Shares”) representing approximately 6.5% of our fully diluted capital, which Knight exercised in full on November 12, 2015. Knight also received a 10-year warrant entitling Knight to purchase up to 4,547,243 shares of our common stock at $0.49 per share (“Knight Warrants”). The beneficial conversion feature of the warrants issued to Knight amounted to $2,553,287 (5,550,625 warrants) and $2,067,258 (4,547,243 warrants), respectively, and was recorded as debt discount of the corresponding debt in 2015. During 2016, this debt discount was fully expensed in conjunction with the cancellation of all warrants and options held by Knight. 17 $10,000,000 August 9, 2017 Loan: On August 9, 2017, we entered into a Second Amendment to Loan Agreement (“Second Amendment”) with Knight, pursuant to which Knight agreed to loan us an additional $10 million, and an ongoing credit facility of up to $20 million, and which amount was borrowed at closing (the “Financing”) for working capital purposes. At closing, we paid Knight an origination fee of $200,000 and a work fee of $100,000 and also paid $100,000 of Knight’s expenses associated with the Loan. The Loan bears interest at 10.5% per annum. The amended Loan Agreement matures on August 8, 2020. We have met all the covenants except for the TTM EBITDA of $5 million during the period ending March 31, 2018. On May 14, 2018, we entered into Loan Amendment Agreement and reduced the TTM EBITA from a minimum of $5 million to $2 million for each twelve months period ending on the last day of each fiscal quarter until September 30, 2018 and we shall maintain a minimum EBITDA of $5 million for the twelve month period ending on the last day of each Fiscal Quarter thereafter, provided that the minimum EBITDA amount shall be increased by an amount equal to 50% of any Additional Tranche advanced to Borrower hereunder. An additional default interest rate of 5% (from 10.5% to 15.5%) applies from April 1, 2018 up to later of i) September 30, 2018; or ii) when Event of Default is cured. The Default Interest Rate will be reduced to 13% if Synergy amends its employment agreement for each and every employee earning $250,000 or more annually through a reduction of individual salary by at least $60,000 in exchange for bonus of no more than $75,000 payable upon Synergy achieving an EBITDA of $13.887 million for calendar year 2018. During the period ending June 30, 2018 the interest rate was reduced to 13% due to reducing payroll expenses. Also, Synergy will maintain Focus Factor Net Sales as measured on a year-end basis of at least USD $15 million for each fiscal year starting with December 31, 2017. The Company also recorded deferred financing costs of $452,869 with respect to the above loan. The Company recognized amortization of deferred financing costs of $37,739 and $78,735 during the three and six months ended June 30, 2018, respectively. Unamortized debt issuance cost as of June 30, 2018 amounted to $314,492. The Company recognized and paid interest expense of $286,361 and $528,444 during the three and six months ended June 30, 2018, respectively. Accrued interest was $0 as of June 30, 2018. The loan balance at June 30, 2018 was $8,500,000. Note 11 – Stockholders’ Equity The total number of shares of all classes of capital stock which the Company is authorized to issue is 300,000,000 shares of common stock with $0.00001 par value. As of both June 30, 2018 and December 31, 2017, there were 89,862,683 shares of the Company’s common stock issued and outstanding. Note 12 – Commitments & Contingencies Litigation: From time to time the Company may become a party to litigation in the normal course of business. Management believes that there are no current legal matters that would have a material effect on the Company’s financial position or results of operations. Employee Commitments The Company and Mr. Kadanoff entered into an employment agreement on October 10, 2017 with an initial term of 3 years. In exchange for his service as Chief Financial Officer, Mr. Kadanoff will receive an annual base salary of $450,000. He received a signing bonus consisting of: (i) 100,000 shares of the Company’s common stock, and (ii) a cash payment equal to the value of 100,000 shares of the Company’s common stock based on a price of $0.55 per share. He received an annual bonus for calendar year 2017 of $37,500. Beginning with calendar year 2018, Mr. Kadanoff will be eligible for an annual target bonus of up to half his base salary. The target bonus will be determined at the discretion of our Board or compensation committee based upon the achievement of financial and other performance-related goals and may be paid in cash or shares of the Company’s common stock. In connection with his employment, Mr. Kadanoff purchased 400,000 shares of our common stock from the Company for a price of $0.55 per share during the year ended December 31, 2017. The Company granted Mr. Kadanoff an option to purchase 1,500,000 shares of the Company’s common stock at an exercise price of $0.55 (the “Initial Option”). The Initial Option vests in three (3) equal annual installments on the first three anniversaries of Mr. Kadanoff’s Start Date with the Company, provided that Mr. Kadanoff remains employed by the Company on each such date. The Initial Option expires on the tenth anniversary of the grant date. Subject to the approval by the Board, during each calendar year of Mr. Kadanoff’s employment with the Company beginning with 2018, the Company will grant to him an option to purchase 500,000 shares of the Company’s common stock (such options collectively the “Additional Options”). The exercise price of each Additional Option will be the Fair Market Value of the common stock on the date each such Additional Option is granted. Each Additional Option will expire on the tenth anniversary of the date of grant of such Additional Option. The Additional Options will vest in three (3) equal annual installments on the first three anniversaries of the date of grant of such Additional Option, provided that Mr. Kadanoff remains employed by the Company on each such date. Upon the occurrence of a Change in Control, the vesting of stock options granted to Mr. Kadanoff will be accelerated subject to his continued service to the Company as of such date and provided further that Mr. Kadanoff’s stock options will be treated no less favorably than those of any other senior executive or Chairman of the Company. The Company and Mr. McCullough entered into an employment agreement on October 17, 2017 (the “Employment Agreement”) with an initial term of 3 years. In exchange for his service as President, Mr. McCullough will receive an annual base salary of $340,000. He received a cash signing bonus of $37,500, to be paid on January 1, 2018, and an additional cash signing bonus of $37,500, to be paid on July 1, 2018, provided that he is employed by the Company through such dates. Mr. McCullough will be eligible for an annual bonus of up to twenty-five percent (25%) of his base salary. The annual bonus will be determined at the discretion of our Board or compensation committee based upon the achievement of financial goals established by the Company’s Chief Executive Officer. Mr. McCullough will also be eligible for additional bonus compensation based on the Company’s achievement of certain annual earnings and retail sales goals established each year by the Company’s Chief Executive Officer. Subject to the Company’s achievement of an annual overall earnings goal and certain adjustments in the event of future acquisitions by the Company, Mr. McCullough will be eligible to receive five percent (5%) of all retail sales by the Company in excess of the annual retail sales goal set by the Chief Executive Officer. The Company granted Mr. McCullough an option to purchase 1,000,000 shares of the Company’s common stock, subject to the approval of the Company’s Board of Directors (the “Option Grant”). The Option Grant vests in three (3) equal annual installments on the first three anniversaries of Mr. McCullough’s start date with the Company, provided that Mr. McCullough remains employed by the Company on each such date. The Option Grant will be granted under the Company’s 2014 Stock Incentive Plan pursuant to a stock grant agreement between the Company and Mr. McCullough. Operating leases On August 16, 2017, the Company entered into a sublease for office space, effective October 1, 2017 through May 2021. Rent expense under this lease will be $19,500 per month, and increasing annually on June 1. The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2018: Year ending December 31: 2018 – remaining six months $ 120,510 2019 245,234 2020 252,591 2021 106,540 2022 - Total $ 724,875 Note 13 – Stock Options On July 4, 2016, the Company granted 500,000 options with an exercise price of $0.70 per share to an employee of the Company. During 2017, 333,333 unvested options were cancelled due to termination of employee. On October 10, 2017, the Company granted 1,000,000 options with an exercise price of $0.70 per share to an employee of the Company. On October 16, 2017, the Company granted 1,500,000 options with an exercise price of $0.55 per share to an employee of the Company. On October 18, 2017, the Company granted 200,000 options with an exercise price of $0.70 per share to an employee of the Company. 18 The following table summarizes the options outstanding, option exercisability and the related prices for the shares of the Company’s common stock issued to employees and consultants under the Plan at June 30, 2018: Options Outstanding Options Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.25 - $0.70 8,666,667 6.72 $ 0.51 6,458,334 $ 0.47 The stock option activity for the six months ended June 30, 2018 is as follows: Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2017 8,666,667 $ 0.51 Granted - - Exercised - - Expired or canceled - - Outstanding at June 30, 2018 8,666,667 $ 0.51 Stock-based compensation expense related to vested options was $119,769 and $239,386 during the three and six months ended June 30, 2018, respectively, which is a component of general and administrative expense in the statement of income. The Company determined the value of share-based compensation for options vesting during the period using the Black-Scholes fair value option-pricing model with the following weighted average assumptions: estimated fair value of Company’s common stock of $0.40-0.74, risk-free interest rate of 0.90-2.23%, volatility of 135-160%, expected lives of 3-10 years, and dividend yield of 0%. Stock options outstanding as of June 30, 2018, as disclosed in the above table, have an intrinsic value of $300,000. As of June 30, 2018, unamortized stock-based compensation costs related to options was $950,997, and will be recognized over a period of 2.25 years. Note 14 – Stock Warrants The following table summarizes the warrants outstanding, warrant exercisability and the related prices for the shares of the Company’s common stock at June 30, 2018: Warrants Outstanding Warrants Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) 5.00 1,000,000 0.47 5.00 1,000,000 5.00 The warrant activity for the six months ended June 30, 2018 is as follows: Warrants Outstanding Weighted Average Exercise Price Outstanding at December 31, 2017 1,000,000 $ 5 Granted - - Exercised - - Expired or canceled - - Outstanding at June 30, 2018 1,000,000 $ 5 Warrants outstanding as of June 30, 2018, as disclosed in the above table, have an intrinsic value of $0. 19 Note 15 – Segments Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis. Net sales attributed to customers in the United States and foreign countries for the three months ended June 30, 2018 and 2017 were as follows: June 30, 2018 June 30, 2017 United States $ 9,242,986 $ 8,475,694 Foreign countries 485,726 843,224 $ 9,728,712 $ 9,318,918 Foreign countries primarily consist of Australia and Canada. The Company’s net sales by product group for the three months ended June 30, 2018 and 2017 were as follows: June 30, 2018 June 30, 2017 Nutraceuticals $ 8,895,489 $ 6,618,264 Over the Counter (OTC) 171,918 572,014 Consumer Goods 290,641 2,041,087 Cosmeceuticals 370,664 87,553 $ 9,728,712 $ 9,318,918 (1) Net sales for any other product group of similar products are less than 10% of consolidated net sales. The Company’s net sales by major sales channel for the three months ended June 30, 2018 and 2017 were as follows: June 30, 2018 June 30, 2017 Online $ 3,611,997 $ 5,479,297 Retail 6,116,715 3,839,621 $ 9,728,712 $ 9,318,918 Net sales attributed to customers in the United States and foreign countries for the six months ended June 30, 2018 and 2017 were as follows: June 30, 2018 June 30, 2017 United States $ 18,270,848 $ 18,420,847 Foreign countries 1,158,725 1,686,390 $ 19,429,573 $ 20,107,237 20 The Company’s net sales by product group for the six months ended June 30, 2018 and 2017 were as follows: June 30, 2018 June 30, 2017 Nutraceuticals $ 17,910,268 $ 16,164,707 Over the Counter (OTC) 334,102 1,075,693 Consumer Goods 562,932 2,772,634 Cosmeceuticals 622,271 94,203 $ 19,429,573 $ 20,107,237 (1) Net sales for any other product group of similar products are less than 10% of consolidated net sales. The Company’s net sales by major sales channel for the six months ended June 30, 2018 and 2017 were as follows: June 30, 2018 June 30, 2017 Online $ 9,024,597 $ 11,460,053 Retail 10,404,976 8,647,184 $ 19,429,573 $ 20,107,237 Long-lived assets (net) attributable to operations in the United States and foreign countries as of June 30, 2018 and December 31, 2017 were as follows: June 30, 2018 December 31, 2017 United States $ 12,890,912 $ 13,613,043 Foreign countries 14,607 5,612 $ 12,905,519 $ 13,618,655 Note 16 – Income Taxes Income tax (benefit) expense was $222,389 and $383,002 for the three and six months ended June 30, 2018, respectively, compared to $167,756 and ($123,711), respectively, for the same periods in 2017. The current provision is attributable to Australian operations and the current tax rate in effect in that country. On December 22, 2017, the Tax Cuts and Jobs Act (the TCJA), which significantly modified U.S. corporate income tax law, was signed into law by President Trump. The TCJA contains significant changes to corporate income taxation, including but not limited to the reduction of the corporate income tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and generally eliminating net operating loss carrybacks, allowing net operating losses to carryforward without expiration, one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including changes to the orphan drug tax credit and changes to the deductibility of research and experimental expenditures that will be effective in the future). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain, including to what extent various states will conform to the newly enacted federal tax law. The Company has not recorded the necessary provisional adjustments in the financial statements in accordance with its current understanding of the TCJA and guidance currently available as of this filing. But is reviewing the TCJA’s potential ramifications, as the Company acts to bring tax compliance up to day. The total deferred tax asset is calculated by multiplying a domestic (US) 25% marginal effective tax rate (estimated state rate of 4%) by the cumulative net operating loss carryforwards (“NOL”). The Company estimates currently it has NOLs, which expire through 2035. Management has determined based on all the available information that a 100% valuation reserve is required. For U.S. purposes, the Company has not completed its evaluation of NOL utilization limitations under Internal Revenue Code, as amended (the “Code”) Section 382/383, change of ownership rules. If the Company has had a change in ownership, the NOL’s would be limited or eliminated, as to the amount that could be utilized each year, based on the Code. The Company has not filed its State & Local Income/Franchise tax returns in States it is required to file for the last few years, so such returns and liability remain open. The Company is currently assessing the requirements to file these returns in states to determine any potential liability, which the Company feels is immaterial. Note 17 – Subsequent Events Management evaluated all activities of the Company through the issuance date of the Company’s unaudited condensed consolidated financial statements and concluded that no subsequent events except as disclosed below have occurred that would require adjustments or disclosure into the unaudited condensed consolidated financial statements. Subsequent to June 30, 2018, the Company made an additional $500,000 payment on $10,000,000 loan. 21 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of the results of operations and financial condition of Synergy for the three and six months ended June 30, 2018 and 2017, should be read in conjunction with the unaudited condensed consolidated financial statements of Synergy, and the notes to those unaudited condensed consolidated financial statements that are included elsewhere in this Form 10-Q. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under the caption, “Cautionary Notice Regarding Forward-Looking Statements” and the “Business” section in our Form 10-K filed on April 2, 2018. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. Overview The Company is in the business of marketing and distributing consumer branded products through various distribution channels primarily in the health and wellness industry. The Company’s strategy is to grow both organically and by future acquisition. Our management’s discussion and analysis of our financial condition and results of operations are only based on our current business and should be read in conjunction with our condensed consolidated financial statements. Key factors affecting our results of operations include revenues, cost of revenues, operating expenses and income and taxation. Non-GAAP Financial Measures We currently focus on Adjusted EBITDA to evaluate our business relationships and our resulting operating performance and financial position. Adjusted EBITDA is defined as EBITDA (net income plus interest expense, income tax expense, depreciation and amortization), further adjusted to exclude certain non-cash expenses and other adjustments as set forth below. We present Adjusted EBITDA because we consider it an important measure of our performance and it is a meaningful financial metric in assessing our operating performance from period to period by excluding certain items that we believe are not representative of our core business, such as certain non-cash items and other adjustments. We believe that Adjusted EBITDA, viewed in addition to, and not in lieu of, our reported results in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), provides useful information to investors. For the three months ended June 30, 2018 Net loss after tax $ (783,393 ) Interest income 1,011 Interest expense 305,687 Taxes 222,389 Depreciation 39,754 Amortization 453,936 EBITDA $ 239,384 Stock-based compensation 119,769 One-time expenses 29,316 Loss on foreign currency translation and transaction 38,678 Adjusted EBITDA $ 427,147 For the six months ended June 30, 2018 Net loss after taxes $ (838,886 ) Interest income (71 ) Interest expense 575,863 Taxes 383,002 Depreciation 76,162 Amortization 910,010 EBITDA $ 1,106,080 Stock-based compensation 239,386 One-time expenses 181,543 Loss on foreign currency translation and transaction 162,252 Adjusted EBITDA $ 1,689,261 EBITDA and Adjusted EBITDA are considered non-GAAP financial measures. EBITDA represents earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA represents EBITDA, further adjusted to exclude the impact of higher-than-normal revenue change other activity and certain expenses and transactions that we believe are not representative of our core operating results, including gain on change in fair value of derivative liability; stock-based compensation; one-time expenses for acquisitions; and the gain on foreign currency translation and transaction. The Company’s definitions of EBITDA and adjusted EBITDA might not be comparable to similarly titled measures reported by other companies. Results of Operations for the Three months Ended June 30, 2018 and 2017 Revenue For the three months ended June 30, 2018, we had revenue of $9,728,712 from sales of our products, as compared to revenue of $9,318,918 for the same period in 2017. We had an increase in Nutraceuticals in 2018 as compared to 2017 due to new customers. We had a decrease in Over the Counter in 2018 as compared to 2017 as 2017 was high due to a sell in to a new customer. We had a decrease in Consumer Goods in 2018 as compared to 2017 as 2017 was the launch of a new product. We had an increase in Cosmeceuticals in 2018 as compared to 2017 due to new customers and new products. The revenue is comprised of the following categories: June 30, 2018 June 30, 2017 Nutraceuticals $ 8,895,489 $ 6,618,264 Over the Counter (OTC) 171,918 572,014 Consumer Goods 290,641 2,041,087 Cosmeceuticals 370,664 87,553 $ 9,728,712 $ 9,318,918 22 Cost of Revenue For the three months ended June 30, 2018, our cost of revenue was $2,744,760. Our cost of revenue for the three months ended June 30, 2017, was $2,462,424. We had an increase in Nutraceuticals in 2018 as compared to 2017 due to higher sales and a different mix of products being sold. We had an increase in Over the Counter in 2018 as compared to 2017 due to a different mix of product being sold. We had a decrease in Consumer Goods in 2018 as compared to 2017 due to a decrease in revenue. We had an increase in Cosmeceuticals in 2018 as compared to 2017 due to an increase in revenue. The cost of revenue is comprised of the following categories: June 30, 2018 June 30, 2017 Nutraceuticals $ 2,618,714 $ 2,224,273 Over the Counter (OTC) 28,622 27,675 Consumer Goods 17,294 197,243 Cosmeceuticals 80,130 13,233 $ 2,744,760 $ 2,462,424 Gross Profit Gross profit was $6,983,952, or 72% for the three months ended June 30, 2018, as compared to gross profit of $6,856,494, or 74% for the same period in 2017, an increase of $127,458, or 1.9%. The decrease in gross profit margin is directly related to increase in sales and selling products with a higher unit cost, thus reducing our margin. Operating Expenses Selling and Marketing Expenses For the three months ended June 30, 2018, our selling and marketing expenses were $5,148,656 as compared to $4,223,712 for the same period in 2017, which is primarily due to increased personnel in our advertising and marketing departments. General and Administrative Expenses For the three months ended June 30, 2018, our general and administrative expenses were $1,475,289. For the three months ended June 30, 2017, our general and administrative expenses were $2,367,969. The decrease is primarily due to better management of operating costs. Depreciation and Amortization Expenses For the three months ended June 30, 2018, our depreciation and amortization expenses were $455,951 as compared to $357,111 for the same period in 2017. The increase is due to more assets owned in 2018. Other Income and Expenses For the three months ended June 30, 2018 and 2017 we had other (income) and expense items of the following: Three months ended June 30, 2018 Three months ended June 30, 2017 Interest income $ 1,011 $ 5 Interest expense 305,687 187,077 Remeasurement loss (gain) on translation of foreign subsidiary 120,623 (105,974 ) Amortization of debt issuance cost 37,739 44,531 Total other expense $ 465,060 $ 125,639 For the three months ended June 30, 2018, we had interest expense of $305,687 as compared to $187,077 for the same period in 2017. The increase was due to increase in the interest rate of Loan 3 from 10% to 13% offset by repayment of Loan 1 and Loan 2. Net Loss For the three months ended June 30, 2018, our net loss was $783,393 as compared to a net loss of $50,181 for the same period in 2017. 23 Results of Operations for the Six months Ended June 30, 2018 and 2017 Revenue For the six months ended June 30, 2018, we had revenue of $19,429,573 from sales of our products, as compared to revenue of $20,107,237 for the same period in 2017. We had an increase in Nutraceuticals in 2018 as compared to 2017 due to new customers. We had a decrease in Over the Counter in 2018 as compared to 2017 as 2017 was high due to a sell in to new customers. We had a decrease in Consumer Goods in 2018 as compared to 2017 as 2017 was the launch of a new product. We had an increase in Cosmeceuticals in 2018 as compared to 2017 due to new customers and new products. The decrease is comprised of the following categories: June 30, 2018 June 30, 2017 Nutraceuticals $ 17,910,268 $ 16,164,707 Over the Counter (OTC) 334,102 1,075,693 Consumer Goods 562,932 2,772,634 Cosmeceuticals 622,271 94,203 $ 19,429,573 $ 20,107,237 Cost of Revenue For the six months ended June 30, 2018, our cost of revenue was $5,554,668. Our cost of revenue for the six months ended June 30, 2017, was $4,964,954. We had an increase in Nutraceuticals in 2018 as compared to 2017 due to higher sales and a different mix of products being sold. We had a decrease in Over the Counter in 2018 as compared to 2017 due to a different mix of product being sold. We had a decrease in Consumer Goods in 2018 as compared to 2017 due to a decrease in revenue. We had an increase in Cosmeceuticals in 2018 as compared to 2017 due to an increase in revenue. The cost of revenue is comprised of the following categories: June 30, 2018 June 30, 2017 Nutraceuticals $ 5,328,360 $ 4,641,186 Over the Counter (OTC) 47,170 47,708 Consumer Goods 57,998 262,264 Cosmeceuticals 121,140 13,796 $ 5,554,668 $ 4,964,954 Gross Profit Gross profit was $13,874,905, or 71% for the six months ended June 30, 2018, as compared to gross profit of $15,142,283, or 75% for the same period in 2017, a decrease of $1,267,378, or 8.4%. The decrease in gross profit margin is directly related to a different mix of products being sold, with higher costs which reduces profit margin. Operating Expenses Selling and Marketing Expenses For the six months ended June 30, 2018, our selling and marketing expenses were $9,401,359 as compared to $7,120,909 for the same period in 2017, which is primarily due to increased personnel in our advertising and marketing departments. 24 General and Administrative Expenses For the six months ended June 30, 2018, our general and administrative expenses were $3,236,145. For the six months ended June 30, 2017, our general and administrative expenses were $4,305,612. The decrease is primarily due to better management of operating costs. Depreciation and Amortization Expenses For the six months ended June 30, 2018, our depreciation and amortization expenses were $907,437 as compared to $649,429 for the same period in 2017. The increase is due to more assets owned in 2018. Other Income and Expenses For the six months ended June 30, 2018 and 2017 we had other (income) and expense items of the following: Six months ended June 30, 2018 Six months ended June 30, 2017 Interest income $ (71 ) $ (10 ) Interest expense 575,863 434,441 Remeasurement gain (loss) on translation of foreign subsidiary 131,321 (91,731 ) Loss on sale of assets - 2,877 Amortization of debt issuance cost 78,735 88,572 Total other expense $ 785,848 $ 434,149 For the six months ended June 30, 2018, we had interest expense of $575,863 as compared to $434,441 for the same period in 2017. The increase was due to increase in the interest rate of Loan 3 from 10% to 13% offset by repayment of Loan 1 and Loan 2. Net (Loss) Income For the six months ended June 30, 2018, our net loss was $838,886 as compared to a net income of $2,508,473 for the same period in 2017. Liquidity and Capital Resources Overview As of June 30, 2018, we had $865,812 cash on hand and a $2,557,687 working capital surplus. In addition, we also had restricted cash of $138,023 which is held for credit card collateral. 25 Six months ended June 30, 2018 and 2017 Net Cash Provided by Operating Activities Net cash provided by operating activities for the six months ended June 30, 2018 was $712,546, compared to $3,301,371 for the same period in 2017. This decrease in net cash provided by operating activities for the six months ended June 30, 2018 was primarily attributable to net loss during the period, an increase in inventory, a decrease in accounts payable and a decrease in accounts receivable. The $712,546 consists of our net loss of $838,886 increased by: Amortization of debt issuance cost $ 78,735 Depreciation and amortization 907,437 Stock based compensation 239,386 Non cash implied interest 42,535 Remeasurement loss on translation of foreign subsidiary 131,321 Foreign currency transaction loss 30,931 Decrease in accounts receivable 244,566 Increase in inventory (313,838 ) Decrease in prepaid expenses 217,779 Increase in deferred revenue 37,843 Decrease in accounts payable and accrued expenses (65,263 ) Net Cash Used in Investing Activities Net cash used in investing activities for the six months ended June 30, 2018 was $194,300, compared to net cash used of $832,270 for the same period in 2017. The decrease in cash used in investing activities during 2018 is attributable to the payout of a development fee in 2017. Payments for acquisition of fixed assets $ (129,087 ) Payment for acquisition of domain name (15,213 ) Purchase of intangible assets (50,000 ) Net Cash Used in Financing Activities Net cash used in financing activities for the six months ended June 30, 2018 was $1,712,500, compared to net cash used of $4,025,000 for the same period in 2017. This is attributable to the repayment of notes. Repayment of notes payable $ (1,712,500 ) Key 2018 Initiatives During 2018, we have plans for organic growth within our current product lines by developing and launching new products. Our technology center in Halifax, Nova Scotia is in full operation providing marketing services to all of our brands. We have new marketing campaigns in process and intend to expand our online presence for each product. While we intend to grow further through additional acquisitions, we feel it is important to also develop our existing products. 26 Contractual Obligations and Off-Balance Sheet Arrangements Contractual Obligations None. Off-Balance Sheet Arrangements None. Inflation The effect of inflation on the Company’s operating results was not significant. Summary of Significant Accounting Policies The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses during the reported periods. The more critical accounting estimates include estimates related to revenue recognition and accounts receivable allowances. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described in Note 2 to our unaudited condensed consolidated financial statements appearing elsewhere in this report. Recent Accounting Pronouncements Note 2 to our unaudited condensed consolidated financial statements appearing elsewhere in this report includes Recent Accounting Pronouncements. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide the information required by this item. ITEM 4. CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures Our Chief Executive Officer (principal executive officer), who is also our Chief Financial Officer (principal financial officer), reviewed the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and concluded that as of June 30, 2018, (i) the Company’s disclosure controls and procedures were not effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “Commission”), and (ii) the Company’s controls and procedures have not been designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Changes in Internal Controls Over Financial Reporting There were no changes in our internal control over financial reporting that occurred during the fiscal quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Inherent Limitations on Effectiveness of Controls The Company’s management does not expect that its disclosure controls or its internal control over financial reporting, when and if effective, will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. 27 PART II – OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results. ITEM 1A. RISK FACTORS As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS None. ITEM 3. DEFAULT UPON SENIOR SECURITIES None. ITEM 4. MINE SAFETY DISCLOSURES Not Applicable. ITEM 5. OTHER INFORMATION None. ITEM 6. EXHIBITS Exhibit Number Description 31.1 Section 302 Certification by the Corporation’s Chief Executive Officer * 31.2 Section 302 Certification by the Corporation’s Chief Financial Officer * 32.1 Section 906 Certification by the Corporation’s Chief Executive Officer * 32.2 Section 906 Certification by the Corporation’s Chief Financial Officer * 101.INS XBRL Instance Document* ** 101.SCH XBRL Taxonomy Extension Schema Document* ** 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document* ** 101.DEF XBRL Taxonomy Extension Definition Linkbase Document* ** 101.LAB XBRL Taxonomy Extension Label Linkbase Document* ** 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document* ** * Filed herewith ** Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections. 28 Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Signatures Title Date /s/ Jack Ross Chief Executive Officer August 14, 2018 /s/ Jeffrey Kadanoff Chief Financial Officer August 14, 2018 29